ATRC-101

ATRC-101 is a monoclonal antibody derived from a human antibody identified using Atreca’s discovery platform. The target of ATRC-101 is a tumor-specific ribonucleoprotein (RNP) complex consisting of polyadenylate-binding protein 1 (PABP1) bound to RNA, shown to be present on a majority of human ovarian, non-small cell lung, colorectal, breast cancers and acral melanoma samples across patients. ATRC-101 is believed to function through Driver Antigen Engagement, a novel mechanism of action in oncology. This mechanism involves systemic delivery of an antibody that, in preclinical models, engages the innate immune system to cause remodeling of the tumor microenvironment and drive T cell-mediated destruction of tumor cells. ATRC-101 has demonstrated robust anti-tumor activity as a single agent in multiple preclinical syngeneic tumor models, including a model in which PD-1 checkpoint inhibitors typically display limited activity.